Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bissonnette

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
The British Journal of Dermatology|May 22, 2018
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension studyF Valenzuela, N J Korman, R Bissonnette, et al.
Dermatology (Basel, Switzerland)|November 22, 2002
A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgarisR Kaufmann, A J Bibby, R Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 7, 2012
Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in DermatologyL R Braathen, C A Morton, N Basset-Seguin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 4, 2012
Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in DermatologyS R Wiegell, H C Wulf, R-M Szeimies, et al.
The British Journal of Dermatology|November 25, 2014
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trialR Bissonnette, L Iversen, H Sofen, et al.
The British Journal of Dermatology|February 9, 2019
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II studyK Reich, P Rich, C Maari, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 22, 2017
Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized studyR Bissonnette, R Haydey, L A Rosoph, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 11, 2014
Effect of biologics on depressive symptoms in patients with psoriasis: a systematic reviewP Fleming, C Roubille, V Richer, et al.
The British Journal of Dermatology|March 29, 2019
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled studyR Bissonnette, C Maari, S Forman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 14, 2020
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trialsT Bieber, J P Thyssen, K Reich, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
The British Journal of Dermatology|May 22, 2018
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension studyF Valenzuela, N J Korman, R Bissonnette, et al.
Dermatology (Basel, Switzerland)|November 22, 2002
A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgarisR Kaufmann, A J Bibby, R Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 7, 2012
Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in DermatologyL R Braathen, C A Morton, N Basset-Seguin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 4, 2012
Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in DermatologyS R Wiegell, H C Wulf, R-M Szeimies, et al.
The British Journal of Dermatology|November 25, 2014
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trialR Bissonnette, L Iversen, H Sofen, et al.
The British Journal of Dermatology|February 9, 2019
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II studyK Reich, P Rich, C Maari, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 22, 2017
Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized studyR Bissonnette, R Haydey, L A Rosoph, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 11, 2014
Effect of biologics on depressive symptoms in patients with psoriasis: a systematic reviewP Fleming, C Roubille, V Richer, et al.
The British Journal of Dermatology|March 29, 2019
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled studyR Bissonnette, C Maari, S Forman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 14, 2020
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trialsT Bieber, J P Thyssen, K Reich, et al.
Pageof 11